Business
PRTC's SPTX: New Positive GlyphAgo Ph1 Dosing Data
PureTech Health plc announced that its founded entity, Seaport Therapeutics, has reported positive multiple-ascending dose data from a Phase 1 trial of GlyphAgo™ (SPT-320) in healthy volunteers. The repeat dosing demonstrated a favorable safety, tolerability, and pharmacokinetic profile consistent with prior data, supporting the advancement of GlyphAgo into two parallel Phase 2 trials for generalized anxiety disorder (GAD). Seaport expects to initiate a Phase 2a trial in the second half of 2026 with topline data anticipated in early 2028, and a Phase 2b trial in the first half of 2027 with topline data expected by the end of 2028. The GlyphAgo program showed therapeutic exposures of agomelatine at doses projected to avoid liver enzyme elevations and reduce the need for liver function testing. Disclaimer*
About this update from Puretech Health Plc
9 June 2026 PureTech Health plc PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, notes that its Founded Entity, Seaport Therapeutics, announced positive data from the multiple-ascending dose (MAD) portion of its Phase 1 proof-of-concept clinical trial evaluating repeat dosing of GlyphAgo™ (SPT-320), a novel, Glyphed oral prodrug of agomelatine, in healthy volunteers. Repeat dosing of GlyphAgo demonstrated a safety, tolerability, and pharmacokinetic (PK) profile consistent with previously reported single-ascending dose (SAD) and crossover data, supporting its planned advancement of GlyphAgo into two parallel Phase 2 trials in patients with generalized anxiety disorder (GAD). Seaport expects to initiate a Phase 2a proof-of pharmacology trial in the second half of 2026. This randomized, double-blind trial of two dose levels of GlyphAgo is designed to demonstrate proof-of-pharmacology by characterizing the potential benefits of GlyphAgo on sleep, including objective measures of sleep architecture, in patients with GAD and sleep disturbance. Topline data from this trial are expected in early 2028. Seaport also expects to initiate a Phase 2b trial of GlyphAgo in the first half of 2027. This randomized, double-blind, placebo-controlled, potentially registration-enabling trial is designed to evaluate the efficacy and safety of GlyphAgo in patients with GAD. Topline data from this trial are expected by the end of 2028. The GlyphAgo program and the underlying Glyph platform were initially advanced at PureTech, applying the Company's strategy of identifying clinically validated pharmacology and overcoming key limitations through targeted innovation. The Glyph platform and related programs are now being advanced by PureTech's Founded Entity, Seaport Therapeutics. The full text of the announcement from Seaport is as follows: Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers Repeat dosing of GlyphAgo confirms favorable sa...
View stock analysis, news, and events for Puretech Health Plc